ABNOVA (TAIWAN) CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.4 TWD | -0.63% |
|
+0.80% | -10.54% |
| Feb. 29 | Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 20 | Abnova Corporation Approves Dividend Distribution for the Year 2023 | CI |
| Sales 2022 | 412M 12.76M | Sales 2023 | 382M 11.84M | Capitalization | 2.13B 65.85M |
|---|---|---|---|---|---|
| Net income 2022 | 74M 2.29M | Net income 2023 | 43M 1.33M | EV / Sales 2022 | 5.2 x |
| Net cash position 2022 | 356M 11.02M | Net cash position 2023 | 415M 12.87M | EV / Sales 2023 | 4.48 x |
| P/E ratio 2022 |
33.5
x | P/E ratio 2023 |
48.8
x | Employees | - |
| Yield 2022 |
1.94% | Yield 2023 |
2.05% | Free-Float | 73.71% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.63% | ||
| 1 week | +0.80% | ||
| Current month | +0.80% | ||
| 1 month | -1.41% | ||
| 3 months | -4.85% | ||
| 6 months | -2.64% | ||
| Current year | -10.54% |
1 week
31.15
31.90
1 month
29.8032.15
Current year
29.8038.00
1 year
29.8038.85
3 years
29.8084.90
5 years
25.25163.00
10 years
21.66163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Ju Jih
CEO | Chief Executive Officer | - | 18-06-30 |
Wilber Huang
CHM | Chairman | 58 | - |
I Ling Tung
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yueh Hung Chen
BRD | Director/Board Member | 60 | 20-06-18 |
Wilber Huang
CHM | Chairman | 58 | - |
Jia Hsie Lin
BRD | Director/Board Member | 73 | 17-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 31.4 | -0.63% | 99,789 |
| 24-05-02 | 31.6 | +1.44% | 72,390 |
| 24-04-30 | 31.15 | -0.32% | 94,463 |
| 24-04-29 | 31.25 | +0.32% | 129,234 |
| 24-04-26 | 31.15 | +0.81% | 101,830 |
End-of-day quote Taiwan S.E., May 02, 2024
More quotes
ABNOVA (TAIWAN) CORPORATION is a Taiwan-based company principally engaged in the manufacturing and sales of antibodies and proteins. The Company's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The Company's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.54% | 58.89M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- 4133 Stock
